Antitumor efficacy in patients with measurable lesions in the phase IIa study (n = 11)
| Outcome . | Patients, n (%) . | 95% CI . |
|---|---|---|
| Overall response rate | 3 (27.3) | 0.0–54.9 |
| Complete response | 0 (0) | 0.0–0.0 |
| Partial response | 3 (27.3) | 0.0–54.9 |
| Stable disease | 3 (27.3) | 0.0–54.9 |
| Progressive disease | 5 (45.5) | 14.6–76.3 |
| Outcome . | Patients, n (%) . | 95% CI . |
|---|---|---|
| Overall response rate | 3 (27.3) | 0.0–54.9 |
| Complete response | 0 (0) | 0.0–0.0 |
| Partial response | 3 (27.3) | 0.0–54.9 |
| Stable disease | 3 (27.3) | 0.0–54.9 |
| Progressive disease | 5 (45.5) | 14.6–76.3 |
Abbreviation: CI, confidence interval.
Antitumor efficacy in patients with measurable lesions in the phase IIa study (n = 11)
| Outcome . | Patients, n (%) . | 95% CI . |
|---|---|---|
| Overall response rate | 3 (27.3) | 0.0–54.9 |
| Complete response | 0 (0) | 0.0–0.0 |
| Partial response | 3 (27.3) | 0.0–54.9 |
| Stable disease | 3 (27.3) | 0.0–54.9 |
| Progressive disease | 5 (45.5) | 14.6–76.3 |
| Outcome . | Patients, n (%) . | 95% CI . |
|---|---|---|
| Overall response rate | 3 (27.3) | 0.0–54.9 |
| Complete response | 0 (0) | 0.0–0.0 |
| Partial response | 3 (27.3) | 0.0–54.9 |
| Stable disease | 3 (27.3) | 0.0–54.9 |
| Progressive disease | 5 (45.5) | 14.6–76.3 |
Abbreviation: CI, confidence interval.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
